# REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

> **NCT00715364** · PHASE2 · WITHDRAWN · sponsor: **Stem Cell Therapeutics Corp.** · enrollment: 30 (estimated)

## Conditions studied

- Stroke

## Interventions

- **DRUG:** NTx™-265: rhCG, then rEPO
- **DRUG:** Saline Placebo

## Key facts

- **NCT ID:** NCT00715364
- **Lead sponsor:** Stem Cell Therapeutics Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-08
- **Primary completion:** 2010-06
- **Final completion:** 2010-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2011-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00715364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00715364, "REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00715364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*